Incadronic acid
As of the edition of 20 October 2026, Incadronic acid is a small molecule: marketed, first approved in 1997 (JP); acts on FDPS.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1997
- Kind
- Small molecule
- First approved
- 1 January 1997 (JP)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Astellas
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Incadronic acid.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| FDPS | Farnesyl pyrophosphate synthase | P14324 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Astellas | Originator | 1997 to now |